FDA Accepts Fast-Acting Meloxicam Acute Pain

The United States Food and Drug Administration (FDA) has accepted a new drug application for a fast-acting formulation of meloxicam intended for the treatment of moderate to severe acute pain. Meloxicam belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) used to relieve pain and inflammation. This formulation is designed to act faster than traditional forms of this medication. The approval of this drug is particularly relevant for anesthesiologists and healthcare professionals involved in pain management. The information was published in Anesthesiology News, a professional journal aimed at anesthesiologists in the United States.